Author
Andrew C. Novick
Other affiliations: June, Mario Negri Institute for Pharmacological Research, Cleveland Clinic Lerner College of Medicine ...read more
Bio: Andrew C. Novick is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Nephrectomy & Transplantation. The author has an hindex of 86, co-authored 539 publications receiving 30822 citations. Previous affiliations of Andrew C. Novick include June & Mario Negri Institute for Pharmacological Research.
Topics: Nephrectomy, Transplantation, Renal cell carcinoma, Kidney, Renal artery
Papers published on a yearly basis
Papers
More filters
TL;DR: Laroscopic partial nephrectomy offered the advantages of less operative time, decreased operative blood loss and a shorter hospital stay and when applied to patients with a single renal tumor 7 cm or less was associated with additional postoperative morbidity compared to open partial ne phrectomy.
1,123 citations
TL;DR: Partial nephrectomy is effective for localized renal cell carcinoma, providing long-term tumor control with preservation of renal function, and was significantly affected by tumor stage, symptoms, tumor laterality and tumor size.
1,016 citations
TL;DR: Nephron sparing surgery provides effective therapy for patients in whom preservation of renal function is a relevant clinical consideration and a long-term functional advantage gained by the maximal preservation of unaffected renal parenchyma without sacrificing cancer control is suggested.
911 citations
TL;DR: It is shown that the cytoplasmic tail of PC1 interacts with tuberin, and the mTOR pathway is inappropriately activated in cyst-lining epithelial cells in human ADPKD patients and mouse models, indicating that PC1 has an important function in the regulation of the m TOR pathway and that this pathway provides a target for medical therapy of AD PKD.
Abstract: Autosomal-dominant polycystic kidney disease (ADPKD) is a common genetic disorder that frequently leads to renal failure. Mutations in polycystin-1 (PC1) underlie most cases of ADPKD, but the function of PC1 has remained poorly understood. No preventive treatment for this disease is available. Here, we show that the cytoplasmic tail of PC1 interacts with tuberin, and the mTOR pathway is inappropriately activated in cyst-lining epithelial cells in human ADPKD patients and mouse models. Rapamycin, an inhibitor of mTOR, is highly effective in reducing renal cystogenesis in two independent mouse models of PKD. Treatment of human ADPKD transplant-recipient patients with rapamycin results in a significant reduction in native polycystic kidney size. These results indicate that PC1 has an important function in the regulation of the mTOR pathway and that this pathway provides a target for medical therapy of ADPKD.
763 citations
TL;DR: Following nephron sparing surgery for localized sporadic renal cell carcinoma cancer-free survival is significantly better in patients with tumors 4 cm.
569 citations
Cited by
More filters
TL;DR: Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) A Collaborative Report from the American Association for Vascular Surgery/Society for V vascular surgery,* Society for Cardiovascular Angiography and Interventions, Society forVascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines.
Abstract: Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,* Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation
3,239 citations
Book•
01 Jan 2004
3,111 citations
Umeå University1, University of Rennes2, University of Texas at Austin3, Charles University in Prague4, Hanover College5, University of Aberdeen6, University of Coimbra7, Radboud University Nijmegen8, St Bartholomew's Hospital9, Ludwig Maximilian University of Munich10, University of Eastern Piedmont11, Netherlands Cancer Institute12
TL;DR: The 2014 RCC guideline has been updated by a multidisciplinary panel using the highest methodological standards, and provides the best and most reliable contemporary evidence base for RCC management.
3,100 citations
2,200 citations
Journal Article•
TL;DR: Although AT(1) receptors mediate most of the known actions of Ang II, the AT(2) receptor contributes to the regulation of blood pressure and renal function and the development of specific nonpeptide receptor antagonists has led to major advances in the physiology, pharmacology, and therapy of the renin-angiotensin system.
Abstract: The cardiovascular and other actions of angiotensin II (Ang II) are mediated by AT(1) and AT(2) receptors, which are seven transmembrane glycoproteins with 30% sequence similarity. Most species express a single autosomal AT(1) gene, but two related AT(1A) and AT(1B) receptor genes are expressed in rodents. AT(1) receptors are predominantly coupled to G(q/11), and signal through phospholipases A, C, D, inositol phosphates, calcium channels, and a variety of serine/threonine and tyrosine kinases. Many AT(1)-induced growth responses are mediated by transactivation of growth factor receptors. The receptor binding sites for agonist and nonpeptide antagonist ligands have been defined. The latter compounds are as effective as angiotensin converting enzyme inhibitors in cardiovascular diseases but are better tolerated. The AT(2) receptor is expressed at high density during fetal development. It is much less abundant in adult tissues and is up-regulated in pathological conditions. Its signaling pathways include serine and tyrosine phosphatases, phospholipase A(2), nitric oxide, and cyclic guanosine monophosphate. The AT(2) receptor counteracts several of the growth responses initiated by the AT(1) and growth factor receptors. The AT(4) receptor specifically binds Ang IV (Ang 3-8), and is located in brain and kidney. Its signaling mechanisms are unknown, but it influences local blood flow and is associated with cognitive processes and sensory and motor functions. Although AT(1) receptors mediate most of the known actions of Ang II, the AT(2) receptor contributes to the regulation of blood pressure and renal function. The development of specific nonpeptide receptor antagonists has led to major advances in the physiology, pharmacology, and therapy of the renin-angiotensin system.
2,063 citations